Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stem Cell Therapy for Cardiovascular Disease-Progress Despite Economic Turmoil

Executive Summary

The Fifth International Conference on Cell Therapy for Cardiovascular Disease is one of the largest medical meetings focused solely on cell-based therapies for cardiac repair and regeneration. While the primary focus during this year's meeting was on cardiac repair, vascular restoration and construction, critical limb ischemia, and noncardiac applications were also presented. Despite a difficult investment environment, optimism remains high with some therapies undergoing approval assessment.

You may also be interested in...



The Future of the Stem Cell Market

The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.

The Future of the Stem Cell Market

The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.

Stem Cell Summit 2008: Moving from Process to Product

More than 40 companies revealed promising research and clinical results at the 2008 Stem Cell Summit in February. Perhaps most impressive was the number of stem cell therapies already in use or tantalizingly close to market launch.

Topics

Related Companies

UsernamePublicRestriction

Register

MT035243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel